Lv41
664 积分 2024-01-17 加入
Expert Consensus on Cytomegalovirus Management in Recipients of CAR‐T Cell and Bispecific Antibody Therapies
1小时前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
29天前
已完结
Platelet Transfusion
30天前
已完结
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes
1个月前
已完结
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
1个月前
已完结
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
1个月前
已完结
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
1个月前
已完结
Long-term Follow-Up of a Phase 1 Study of Arlocabtagene Autoleucel (arlo-cel; BMS-986393) in Patients With Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM)
1个月前
已完结
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
1个月前
已完结
Synergizing artificial intelligence with in vivo CAR-T cell generation: A new paradigm for democratized immunotherapy
1个月前
已完结
皖公网安备34019202002308
